Radical Nephrectomy 

  • Author: Richard A Santucci, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS   more...
 
Updated: Aug 16, 2011
 

Background

Nephrectomy has many indications, for both simple and radical approaches.

A simple nephrectomy is indicated in patients with irreversible kidney damage due to symptomatic chronic infection, obstruction, calculus disease, or severe traumatic injury. Simple nephrectomy is also indicated to treat renovascular hypertension due to noncorrectable renal artery disease or severe unilateral parenchymal damage caused by nephrosclerosis, pyelonephritis, reflux dysplasia, or congenital dysplasia of the kidney.

Radical nephrectomy is the treatment of choice for localized renal cell carcinoma (RCC). In certain circumstances, radical nephrectomy is also indicated to treat locally advanced RCC and metastatic RCC.

With the advent and increasingly mainstream use of abdominal CT scanning and ultrasound imaging in recent years for various abdominal and, occasionally, chest complaints, incidental detection of RCC has increased in asymptomatic patients. Currently, more than 50% of RCC cases are detected incidentally. These tumors tend to be smaller and of lower stage, resulting in better survival rates, lower recurrence rates, and lower metastasis rates than RCC detected in symptomatic patients. Symptomatic RCC presents at a significantly higher stage and grade, and tumors are substantially more aggressive than incidentally discovered lesions, particularly at later stages.

Next

History of the Procedure

  • 1869: Gustav Simon performs the first planned nephrectomy for the treatment of ureterovaginal fistula.
  • 1878: Kocher performs an anterior transperitoneal nephrectomy through a midline incision.
  • 1881: Morris performs the first nephrolithotomy; he later defines the terms nephrolithiasis, nephrolithotomy, nephrectomy, and nephrotomy.
  • 1884: Wells performs the first partial nephrectomy to remove a perirenal fibrolipoma.
  • 1913: Berg uses a transverse abdominal incision for securing the renal pedicle to remove vena caval tumor thrombi through a cavotomy.
  • Early-to-mid 1900s: The retroperitoneal flank approach becomes preferred because of the lower incidence of peritonitis and other abdominal complications associated with the anterior approach.
  • 1950s: The development of safe abdominal techniques leads to the revival of the anterior approach.
  • 1963: Robson described radical nephrectomy and the improvement in survival with the procedure.[1]
  • 1990: Clayman performs the first laparoscopic nephrectomy at Washington University.
Previous
Next

Epidemiology

Frequency

Overall, the vast majority of incidentally discovered renal masses are cysts. Abdominal CT scanning reveals a simple renal cyst in 25% of patients older than 40 years. Others report the presence of renal cysts in more than 50% of men older than 50 years. When a patient presents with a renal mass in association with macroscopic hematuria, flank pain, or a palpable mass, the chance of the mass being renal cell cancer is approximately 50%. Other renal masses, specifically angiomyolipoma, renal pelvic tumors, and other benign lesions, all are relatively uncommon, accounting for approximately 5% of all renal masses among asymptomatic patients.

Previous
Next

Etiology

Several factors have been associated with increased risk of RCC.

  • Obesity and cigarette smoking are the most consistently established causal risk factors, accounting for more than 30% and 20% of renal cell cancers, respectively.[2]
  • Hypertension as an independent factor is associated with increased risk of RCC.[2]
  • Analgesic use was once considered to be a more significant etiology than recent reports have indicated.[2]
  • A family history of RCC is associated with a 2- to 3-fold increased risk of RCC. However, a familial predisposition is identified in less than 2% of RCC cases.[2] The identification of families with a predisposition to the development of renal neoplasms, including von Hippel-Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt-Hogg-Dubé (BHD), and hereditary leiomyomatosis and renal cell cancer (HLRCC), has enabled the identification of the different genes for these cancers.[3]
Previous
Next

Presentation

Traditionally, RCC is diagnosed after any or all of the classic triad of symptoms, ie, flank pain, palpable mass, and hematuria, have been investigated (see image below). However, with the increased use of imaging techniques over the past 2 decades, up to 72% of RCC cases are identified incidentally after investigation for unrelated abdominal pain or other non-urologic symptoms.

Large right renal tumor visible as an abdominal maLarge right renal tumor visible as an abdominal mass.

Presenting symptoms may be related to bleeding in the tumor, resulting in stretching of the renal capsule and pain. Bleeding into the collecting system also causes pain due to clot formation and ureteral obstruction. Local invasion and clot extension into the vena cava is suspected in patients presenting with lower extremity edema, varicocele, dilated superficial abdominal veins, proteinuria, pulmonary embolism, a right atrial mass, or no function in the involved kidney.

Lack of early warning signs characterizes RCC, resulting in a high proportion (one third) of patients with metastases at diagnosis. These patients face a dismal prognosis; the 5-year survival rate is less than 10% and the average survival is only 6-12 months. Weight loss, fever, and night sweats may suggest metastasis.

Previous
Next

Indications

Radical nephrectomy remains the procedure of choice for surgically resectable lesions. Relapse occurs in 20-30% of patients with completely resected RCC after radical nephrectomy. Radical nephrectomy is also indicated in patients with metastatic disease as part of immunotherapy or the new chemotherapy protocol as a palliative procedure in cases of intractable pain and bleeding. Many cases are now treated with new FDA-approved tyrosine kinase inhibitors as adjuvant therapy. In addition, several new medications are now in phase II and phase III trials for the management of metastatic renal cancer. Results so far have been promising in terms of improving survival and delaying progression.

Predictors of relapse include symptomatic disease, high Fuhrman grade of tumor, high pathological stage, microvascular invasion, and necrosis. In these patients, neither postnephrectomy radiation therapy nor adjuvant interferon-alpha administration delays relapse or increases overall survival rates compared with observation alone. Therefore, observation remains the standard of care following radical nephrectomy for renal cell cancer.

Previous
Next

Relevant Anatomy

The kidneys are paired vital organs located on either side of the vertebral column and embedded in the intermediate stratum of retroperitoneal connective tissue. The perirenal fascia, also called the Gerota fascia, encloses both the kidneys and adrenal glands.

Renal malignancies tend to remain within this fascia and can be excised completely by removing the kidney and its surrounding fascia as a single entity. In most individuals, a single renal artery and vein enters the kidney medially through the renal hilum, but multiple renal arteries are not uncommon.

The renal artery arises from the lateral aspect of the aorta, just below the superior mesenteric artery, and passes behind the renal vein. The main renal artery then divides into 4-5 segmental vessels to supply the corresponding renal parenchyma. These segmental vessels are end arteries without collateral circulation; thus, any injury to the renal artery at any level results in infarction of the corresponding parenchyma.

Unlike the renal arteries, the renal parenchymal veins intercommunicate freely among the various renal segments. Usually, a single renal vein joins the inferior vena cava on its lateral aspect. Multiple renal arteries occur unilaterally in 23% of the population, whereas multiple renal veins are less common.

The right adrenal gland lies above the kidney posterolateral to the inferior vena cava. The inferior phrenic artery is the main blood supply, with additional branches from the aorta and renal artery. The venous drainage usually is through a common vein on the right, exiting the apex of the gland and entering the posterior surface of the inferior vena cava. This vein is short and fragile and is a common source of bleeding during right adrenalectomy. The left vein empties directly into the left renal vein approximately 3 cm from the inferior vena cava and often opposite to the gonadal vein. Not well-recognized is the left inferior phrenic vein, which typically communicates with the adrenal vein but then courses medially and can be injured during dissection of the medial edge of the gland.

The paired gonadal arteries arise from the anterolateral aorta at a level somewhat below the renal vessels. Occasionally, a gonadal artery arises from the ipsilateral renal artery or from the aorta above the level of the renal vessels. In their retroperitoneal course, the gonadal arteries pass anteriorly to the ureter on either side. Gonadal veins parallel the gonadal arteries in their inferior course but, superiorly, tend to be more lateral and closer to the ipsilateral ureter. The left gonadal vein usually enters the inferior aspect of the left renal vein perpendicularly. The right gonadal vein usually drains obliquely into the right lateral aspect of the inferior vena cava, below the level of the right adrenal vein.

Previous
Next

Contraindications

Nephron-sparing surgery (NSS) has become a successful alternative treatment to radical nephrectomy for RCC when a functioning renal parenchyma must be preserved, such as in patients with (1) bilateral RCC; (2) RCC involving a solitary functioning kidney; (3) chronic renal insufficiency; or (4) unilateral RCC with a functioning opposite kidney at risk for future impairment from an intercurrent disease, such as calculus disease, renal artery stenosis, diabetes, hypertension, or nephrosclerosis. Novick played an important role in establishing NSS, proving its efficacy and safety, and describing the ideal technique.[4]

Several studies have confirmed that NSS provides curative treatment that is as equally effective as radical nephrectomy in patients who have a single, small (< 4 cm in diameter), unilateral, localized RCC. NSS is also becoming increasingly recognized as effective treatment for small, select, incidentally discovered tumors, even when the contralateral kidney is normal. Recent reports suggest using NSS for tumors up to 7 cm in diameter, particularly for polar tumors that do not extend into the renal hilum.

The major disadvantage of NSS is the small risk (1-6%) of local tumor recurrence due to undetected microscopic multifocal RCC in the remnant of the operated kidney. Partial nephrectomy is also associated with a higher risk of bleeding and urine leak. Despite this higher complication rate, saving the normal nephrons in the kidney reducesthe risk of impaired kidney function and its associated complications.

Laparoscopic partial nephrectomy is a new modality that is increasingly used. It offers faster convalescence than open partial nephrectomy. However, it is associated with a higher rates of positive margins, major intraoperative complications, and urologic complication rates. Laparoscopic partial nephrectomy should be reserved for patients with small exophytic tumors and should be performed by a well-trained laparoscopic urologist.

Previous
Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Richard A Santucci, MD, FACS  Specialist-in-Chief, Department of Urology, Detroit Medical Center; Chief of Urology, Detroit Receiving Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State University College of Medicine

Richard A Santucci, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, and Société Internationale d'Urologie (International Society of Urology)

Disclosure: Nothing to disclose.

Coauthor(s)

Hosam S Al-Qudah, MD  Consultant Urologist, Department of General Surgery, Saad Specialist Hospital, Al-Khobar, Saudi Arabia

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael Grasso III, MD  Director of Endourology, Lenox Hill Hospital; Professor and Vice Chairman, Department of Urology, New York Medical College

Michael Grasso III, MD is a member of the following medical societies: American Medical Association, American Urological Association, Endourological Society, Medical Society of the State of New York, National Kidney Foundation, Société Internationale d'Urologie (International Society of Urology), and Society of Laparoendoscopic Surgeons

Disclosure: Karl Storz Endoscopy Consulting fee Consulting; Boston Scientific Consulting fee Consulting; Cook Urologic Consulting fee Consulting

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Martin I Resnick, MD †  Former Lester Persky Professor and Chair, Department of Urology, Former Professor, Department of Oncology, Case Western Reserve University School of Medicine

Martin I Resnick, MD † is a member of the following medical societies: American College of Surgeons, American Federation for Medical Research, American Institute of Ultrasound in Medicine, American Medical Association, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Society of Andrology, American Surgical Association, American Urological Association, Association for Academic Surgery, Endocrine Society, National Kidney Foundation, Ohio Urological Society, and Pan American Medical Association

Disclosure: Nothing to disclose.

J Stuart Wolf Jr, MD, FACS  The David A Bloom Professor of Urology, Director, Division of Endourology and Stone Disease, Department of Urology, University of Michigan Medical School

J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology

Disclosure: Nothing to disclose.

Chief Editor

Bradley Fields Schwartz, DO, FACS  Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists

Disclosure: Nothing to disclose.

References
  1. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol. Jan 1963;89:37-42. [Medline].

  2. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. Dec 2006;176(6 Pt 1):2353-8. [Medline].

  3. Sudarshan S, Linehan WM. Genetic basis of cancer of the kidney. Semin Oncol. Oct 2006;33(5):544-51. [Medline].

  4. Novick AC, Stewart BH, Straffon RA, Banowsky LH. Partial nephrectomy in the treatment of renal adenocarcinoma. J Urol. Dec 1977;118(6):932-6. [Medline].

  5. Glazer A, Novick AC. Preoperative transesophageal echocardiography for assessment of vena caval tumor thrombi: a comparative study with venacavography and magnetic resonance imaging. Urology. Jan 1997;49(1):32-4. [Medline].

  6. Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. Jul 2009;74(1):154-9. [Medline].

  7. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. Oct 1999;162(4):1282-4; discussion 1284-5. [Medline].

  8. Link RE, Bhayani SB, Allaf ME, et al. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol. May 2005;173(5):1690-4. [Medline].

  9. Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int. Mar 2006;97(3):505-8. [Medline].

  10. Yokoyama H, Tanaka M. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy?. BJU Int. Mar 2005;95(4):526-9. [Medline].

  11. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology. Apr 1986;27(4):291-301. [Medline].

  12. Hegarty NJ, Gill IS, Desai MM, Remer EM, O'Malley CM, Kaouk JH. Probe-ablative nephron-sparing surgery: cryoablation versus radiofrequency ablation. Urology. Jul 2006;68(1 Suppl):7-13. [Medline].

  13. Kaouk JH, Aron M, Rewcastle JC, Gill IS. Cryotherapy: clinical end points and their experimental foundations. Urology. Jul 2006;68(1 Suppl):38-44. [Medline].

  14. Al-Qudah HS, Rodriguez AR, Sexton WJ. Laparoscopic management of kidney cancer: updated review. Cancer Control. Jul 2007;14(3):218-30. [Medline]. [Full Text].

  15. Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. Jun 2008;179(6):2136-40; discussion 2140-1. [Medline].

  16. Clayman RV, Surya V, Miller RP, Reinke DB, Fraley EE. Pursuit of the renal mass. Is ultrasound enough?. Am J Med. Aug 1984;77(2):218-23. [Medline].

  17. Cookson MS. Radical Nephrectomy. In: Graham Jr SD, Glenn JF, eds. Glenn's Urologic Surgery. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1998:61-72.

  18. Cooney MM, Remick SC, Vogelzang NJ. Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol. Sep 2005;6(5):357-65. [Medline].

  19. Desai MM, Strzempkowski B, Matin SF, et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol. Jan 2005;173(1):38-41. [Medline].

  20. Finley DS, Beck S, Box G, Chu W, Deane L, Vajgrt DJ. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol. Aug 2008;180(2):492-8; discussion 498. [Medline].

  21. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. Nov 2005;16(9):1099-106. [Medline].

  22. Gill IS, Clayman RV, McDougall EM. Advances in urological laparoscopy. J Urol. Oct 1995;154(4):1275-94. [Medline].

  23. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol. Oct 1994;152(4):1082-5. [Medline].

  24. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. Mar 1990;143(3):468-73; discussion 473-4. [Medline].

  25. Harryman OA, Davenport K, Keoghane S, Keeley FX, Timoney AG. A comparative study of quality of life issues relating to open versus laparoscopic nephrectomy: a prospective pragmatic study. J Urol. Mar 2009;181(3):998-1003; discussion 1003. [Medline].

  26. Hinman F. 1998. In: Atlas of Urologic Surgery. 2nd ed. Philadelphia, Pa: WB Saunders; 853-1056.

  27. Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial. Dec 2004;8(6):468-73. [Medline].

  28. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. Oct 2006;33(5):576-82. [Medline].

  29. Jennings SB, Linehan WM. Renal, Perirenal, and Ureteral Neoplasms. In: Gillenwater JJ, Grayhack JT, Howards SS, Ducket JW. Adult and Pediatric Urology. 3rd ed. St. Louis: Mo: Mosby; 1996:643-94.

  30. Kabalin JN. Surgical anatomy of the retroperitoneum, kidneys, and ureters. In: Walsh PC, Vaughan Jr D, Wein AJ, Retik AB, Zorab R. Campbell's Urology. Vol 1. 7th ed. Philadelphia, Pa: WB Saunders; 1998:49-88.

  31. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. May 1987;13(5):665-72. [Medline].

  32. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology. Jul 2000;56(1):58-62. [Medline].

  33. Malaeb BS, Martin DJ, Littooy FN, et al. The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU Int. May 2005;95(7):977-81. [Medline].

  34. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. Oct 2006;33(5):527-33. [Medline].

  35. Mevorach RA, Segal AJ, Tersegno ME, Frank IN. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology. Jun 1992;39(6):519-22. [Medline].

  36. Novick AC. Partial nephrectomy for renal cell carcinoma. Urol Clin North Am. May 1987;14(2):419-33. [Medline].

  37. Novick AC, Streem SB. Surgery of the kidney. In: Walsh PC, Vaughan Jr D, Wein AJ, Retik AB, Zorab R, eds. Campbell's Urology. Vol 3. 7th ed. Philadelphia, Pa: WB Saunders; 1998:2973-3051.

  38. O'Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol. May 2009;181(5):2009-17. [Medline].

  39. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already?. Curr Opin Urol. Mar 2005;15(2):75-8. [Medline].

  40. Parmar S, Rademaker AW, Fung BB, Kozlowski JM, Kuzel TM. Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience. Med Oncol. 2005;22(4):399-405. [Medline].

  41. Peycelon M, Hupertan V, Comperat E, Renard-Penna R, Vaessen C, Conort P. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. Jan 2009;181(1):35-41. [Medline].

  42. Pizzocaro G, Piva L, Costa A. Adjuvant interferon to radical nephrectomy in Robson's stage II and III renal cell cancer, a multicenter randomized study with some biological evaluations. Proc Am Soc Clin Oncol. 1997;16:318A.

  43. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. Mar 1969;101(3):297-301. [Medline].

  44. Rodriguez A, Sexton WJ. Management of locally advanced renal cell carcinoma. Cancer Control. Jul 2006;13(3):199-210. [Medline].

  45. Rodriguez R, Chan DY, Bishoff JT, et al. Renal ablative cryosurgery in selected patients with peripheral renal masses. Urology. Jan 2000;55(1):25-30. [Medline].

  46. Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology. May 2009;73(5):1077-82. [Medline].

  47. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. Jan 2005;173(1):48-51. [Medline].

  48. Steinberg AP, Finelli A, Desai MM, et al. Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. J Urol. Dec 2004;172(6 Pt 1):2172-6. [Medline].

  49. Tosaka A, Ohya K, Yamada K, et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol. Nov 1990;144(5):1097-9. [Medline].

  50. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. Feb 2000;163(2):426-30. [Medline].

  51. Varkarakis IM, Bhayani SB, Allaf ME, Inagaki T, Gonzalgo ML, Jarrett TW. Laparoscopic-assisted nephrectomy with inferior vena cava tumor thrombectomy: preliminary results. Urology. Nov 2004;64(5):925-9. [Medline].

  52. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. Jul 1999;162(1):43-5. [Medline].

  53. Zeman RK, Cronan JJ, Rosenfield AT, Lynch JH, Jaffe MH, Clark LR. Renal cell carcinoma: dynamic thin-section CT assessment of vascular invasion and tumor vascularity. Radiology. May 1988;167(2):393-6. [Medline].

Previous
Next
 
Large right renal tumor visible as an abdominal mass.
CT finding that confirms a huge right renal mass.
Renal tumor after surgical removal.
Nephrectomy for multicystic kidney.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.